Back to Search
Start Over
The inhibitory effect of Cordycepin on the proliferation of cisplatin-resistant A549 lung cancer cells.
- Source :
-
Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2018 Apr 06; Vol. 498 (3), pp. 431-436. Date of Electronic Publication: 2018 Feb 26. - Publication Year :
- 2018
-
Abstract
- The goal of this study is to determine the anti-cancer mechanism of Cordycepin in A549 Cisplatin-Resistance (CR) lung cancer cells. Cordycepin inhibited the viability of A549CR cells in a dose-dependent manner. The cell inhibition was due to induction of apoptosis in the cells treated with Cordycepin by activation of caspase -3, -8 and -9 activities. The cell cycle analysis showed that accumulation of Sub G1 was observed in Cordycepin-treated with A549CR lung cancer cells. Based on the data of expression profile analysis of cell signaling proteins using IPS-FPAA, H-Ras was down-regulated in Cordycepin-treated A549CR cells. Collectively, anti-proliferative function of Cordycepin was due to stimulation of the cell apoptosis and the cell cycle arrest via caspases activation and down-regulation of H-Ras.<br /> (Copyright © 2018 Elsevier Inc. All rights reserved.)
- Subjects :
- A549 Cells
Apoptosis drug effects
Caspases metabolism
Cell Cycle drug effects
Cell Cycle Proteins genetics
Cell Cycle Proteins metabolism
Down-Regulation drug effects
Enzyme Activation drug effects
Genes, ras drug effects
Humans
Lung Neoplasms genetics
Lung Neoplasms metabolism
Signal Transduction drug effects
Transcriptome drug effects
Antineoplastic Agents pharmacology
Cell Proliferation drug effects
Cisplatin pharmacology
Deoxyadenosines pharmacology
Drug Resistance, Neoplasm drug effects
Lung Neoplasms drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1090-2104
- Volume :
- 498
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Biochemical and biophysical research communications
- Publication Type :
- Academic Journal
- Accession number :
- 29496448
- Full Text :
- https://doi.org/10.1016/j.bbrc.2018.02.188